Aptose Biosciences Stock Current Liabilities
| APS Stock | CAD 0.27 0.07 20.59% |
Aptose Biosciences fundamentals help investors to digest information that contributes to Aptose Biosciences' financial success or failures. It also enables traders to predict the movement of Aptose Stock. The fundamental analysis module provides a way to measure Aptose Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aptose Biosciences stock.
As of the 23rd of November 2024, Total Current Liabilities is likely to grow to about 16 M, while Non Current Liabilities Total is likely to drop about 590 K. Aptose | Current Liabilities |
Aptose Biosciences Company Current Liabilities Analysis
Aptose Biosciences' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Aptose Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Aptose Biosciences is extremely important. It helps to project a fair market value of Aptose Stock properly, considering its historical fundamentals such as Current Liabilities. Since Aptose Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aptose Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aptose Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Aptose Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Aptose Biosciences has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all Canada stocks is 100.0% higher than that of the company.
Aptose Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aptose Biosciences from analyzing Aptose Biosciences' financial statements. These drivers represent accounts that assess Aptose Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aptose Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 19.0M | 23.9M | 8.0M | 3.6M | 3.2M | 4.6M | |
| Enterprise Value | (59.3M) | (92.4M) | (30.5M) | (32.1M) | (36.9M) | (35.1M) |
Aptose Fundamentals
| Return On Equity | -6.94 | ||||
| Return On Asset | -1.36 | ||||
| Current Valuation | (3.86 M) | ||||
| Shares Outstanding | 19.52 M | ||||
| Shares Owned By Insiders | 15.87 % | ||||
| Shares Owned By Institutions | 16.68 % | ||||
| Number Of Shares Shorted | 2.25 K | ||||
| Price To Earning | (1.85) X | ||||
| Price To Book | 68.22 X | ||||
| EBITDA | (52.27 M) | ||||
| Net Income | (51.21 M) | ||||
| Cash And Equivalents | 36.37 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 5.00 % | ||||
| Current Ratio | 11.27 X | ||||
| Book Value Per Share | (0.36) X | ||||
| Cash Flow From Operations | (44.59 M) | ||||
| Short Ratio | 0.45 X | ||||
| Earnings Per Share | (4.08) X | ||||
| Target Price | 31.02 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.36 | ||||
| Market Capitalization | 5.27 M | ||||
| Total Asset | 12.99 M | ||||
| Retained Earnings | (515.54 M) | ||||
| Working Capital | (3.38 M) | ||||
| Net Asset | 12.99 M |
About Aptose Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aptose Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aptose Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aptose Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aptose Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Aptose Stock
| 0.47 | WMT | Walmart Inc CDR | PairCorr |
| 0.36 | TSLA | Tesla Inc CDR | PairCorr |
| 0.31 | BRK | Berkshire Hathaway CDR | PairCorr |
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.